Gilead suffers IP reverse in China
China has rejected a patent application of Gilead, related to a precursor drug to Sovaldi
Reuters noted:
Officials at China's State Intellectual Property Office did not confirm the decision when contacted by Reuters, but a notice posted on the body's website said Gilead's application for "nucleoside phosphramidates", a kind of prodrug, had recently been rejected.
China's move follows a decision by India's patent office in January to reject Gilead's patent application for Sovaldi, finding it was not inventive enough. Gilead is appealing the ruling.
link: http://uk.reuters.com/article/2015/06/19/us-gilead-sciences-sovaldi-patents-idUKKBN0OZ0A620150619
Reuters noted:
Officials at China's State Intellectual Property Office did not confirm the decision when contacted by Reuters, but a notice posted on the body's website said Gilead's application for "nucleoside phosphramidates", a kind of prodrug, had recently been rejected.
China's move follows a decision by India's patent office in January to reject Gilead's patent application for Sovaldi, finding it was not inventive enough. Gilead is appealing the ruling.
link: http://uk.reuters.com/article/2015/06/19/us-gilead-sciences-sovaldi-patents-idUKKBN0OZ0A620150619
posted by Lawrence B. Ebert at 6:35 AM
0 Comments:
Post a Comment
<< Home